3Oakervee H E,Popat R, Curry N, et al. PAD CombinationTherapy (PS -341/Bortezomib,Doxorubicin and Dexametha-sone) for Previously Untreated Patients with Multipe Myeloma[J].Br J Haematol, 2005,129(6):755-762.
6ADAMS J, PALOMBELLA VJ, SAUSVILLE EA, et al. Proteasome inhibitors:a novel class of potent and effective antitumor agents[J]. Cancer Res, 1999, 59(11) :2615 -2622.
7RICHARDSON PG, BARLOGIE B, BERENSON J NJ, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[ J]. N Engl J Med, 2003, 348 (26) :2609 - 2617.
8NORRBY SR. Carbapenems in serious infection a risk benefit assessment[J]. Drug Saf, 2000, 22(3):191 -194.
9ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS, et al. Phase 1 trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies [ J ]. J Clin Oncol, 2002, 20 ( 22 ) :4420 - 4427.
10RICHARDSON P G,BARLOGIE B,BERENSON J,et al.A phase 2 study of bortezomib in relapsed refractory myeloma[J].N Engl J Med,2003,348(26):2609-2617.
1Brnxelle J, Pinchinat S.Effectiveness of antiviral treatment on acute phase of herpes zoster and development of post herpetic neuralgia: review of international publications[J].Mdd Mal Infect, 2012, 42(2): 53-58.
2Gupta S, Gnpta S, Aggarwal K, et al.Necrodestructive herpes zoster[J]. Indian Journal of Dermatology, 2012, 57(2): 136.
3Opstelten W, Eekhof J, Neven A K, et al.Treatment of herpes zoster[J]. Can Fam Physician, 2008, 54(3): 373-377.
4Broussard K C, Berger T G, Rosenblum M, et al.Erosive pustular dermatosis of the scalp: a review with a focus on dapsone therapy[J]. Journal of the American Academy of Dermatology, 2012, 66(4): 680- 686.
